B-cell depletion with ofatumumab may reduce pro-inflammatory cytokine production relevant to both MS and eosinophilic inflammation, while IL-5 inhibition with mepolizumab attenuates eosinophil-mediated tissue damage, which may also influence neuroinflammation (Figure 1). Here, IL5 is linked to myeloid sarcoma.